<!DOCTYPE html>
<!-- saved from url=(0076)https://us21.campaign-archive.com/?u=506ac9dc6e88b1ae3fedcece9&id=6357ab3f35 -->
<html xmlns:fb="http://www.facebook.com/2008/fbml" xmlns:og="http://opengraph.org/schema/"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        
<meta property="og:title" content="bancroft ai - Gracell&#39;s Clinical Trial, Ionis-Roche Partnership, VBI&#39;s Vaccine Progress">
<meta property="fb:page_id" content="43929265776">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
<meta name="referrer" content="origin">        
<!--[if gte mso 15]>
<xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
<o:PixelsPerInch>96</o:PixelsPerInch>
</o:OfficeDocumentSettings>
</xml>
<![endif]-->

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>bancroft ai - Gracell's Clinical Trial, Ionis-Roche Partnership, VBI's Vaccine Progress</title>
<link rel="stylesheet" href="./wholething_files/css"><style>          img{-ms-interpolation-mode:bicubic;} 
          table, td{mso-table-lspace:0pt; mso-table-rspace:0pt;} 
          .mceStandardButton, .mceStandardButton td, .mceStandardButton td a{mso-hide:all !important;} 
          p, a, li, td, blockquote{mso-line-height-rule:exactly;} 
          p, a, li, td, body, table, blockquote{-ms-text-size-adjust:100%; -webkit-text-size-adjust:100%;} 
          @media only screen and (max-width: 480px){
            body, table, td, p, a, li, blockquote{-webkit-text-size-adjust:none !important;} 
          }
          .mcnPreviewText{display: none !important;} 
          .bodyCell{margin:0 auto; padding:0; width:100%;}
          .ExternalClass, .ExternalClass p, .ExternalClass td, .ExternalClass div, .ExternalClass span, .ExternalClass font{line-height:100%;} 
          .ReadMsgBody{width:100%;} .ExternalClass{width:100%;} 
          a[x-apple-data-detectors]{color:inherit !important; text-decoration:none !important; font-size:inherit !important; font-family:inherit !important; font-weight:inherit !important; line-height:inherit !important;} 
            body{height:100%; margin:0; padding:0; width:100%; background: #ffffff;}
            p{margin:0; padding:0;} 
            table{border-collapse:collapse;} 
            td, p, a{word-break:break-word;} 
            h1, h2, h3, h4, h5, h6{display:block; margin:0; padding:0;} 
            img, a img{border:0; height:auto; outline:none; text-decoration:none;} 
            a[href^="tel"], a[href^="sms"]{color:inherit; cursor:default; text-decoration:none;} 
            li p {margin: 0 !important;}
            .ProseMirror a {
                pointer-events: none;
            }
            @media only screen and (max-width: 480px){
                body{width:100% !important; min-width:100% !important; } 
                body.mobile-native {
                    -webkit-user-select: none; user-select: none; transition: transform 0.2s ease-in; transform-origin: top center;
                }
                body.mobile-native.selection-allowed a, body.mobile-native.selection-allowed .ProseMirror {
                    user-select: auto;
                    -webkit-user-select: auto;
                }
                colgroup{display: none;}
                img{height: auto !important;}
                .mceWidthContainer{max-width: 660px !important;}
                .mceColumn{display: block !important; width: 100% !important;}
                .mceColumn-forceSpan{display: table-cell !important; width: auto !important;}
                .mceBlockContainer{padding-right:16px !important; padding-left:16px !important;} 
                .mceBlockContainerE2E{padding-right:0px; padding-left:0px;} 
                .mceSpacing-24{padding-right:16px !important; padding-left:16px !important;}
                .mceFooterSection .mceText, .mceFooterSection .mceText p{font-size: 16px !important; line-height: 140% !important;}
                .mceText, .mceText p{font-size: 16px !important; line-height: 140% !important;}
                h1{font-size: 30px !important; line-height: 120% !important;}
                h2{font-size: 26px !important; line-height: 120% !important;}
                h3{font-size: 20px !important; line-height: 125% !important;}
                h4{font-size: 18px !important; line-height: 125% !important;}
            }
            @media only screen and (max-width: 640px){
                .mceClusterLayout td{padding: 4px !important;} 
            }
            div[contenteditable="true"] {outline: 0;}
            .ProseMirror .empty-node, .ProseMirror:empty {position: relative;}
            .ProseMirror .empty-node::before, .ProseMirror:empty::before {
                position: absolute;
                left: 0;
                right: 0;
                color: rgba(0,0,0,0.2);
                cursor: text;
            }
            .ProseMirror .empty-node:hover::before, .ProseMirror:empty:hover::before {
                color: rgba(0,0,0,0.3);
            }
            .ProseMirror h1.empty-node:only-child::before,
            .ProseMirror h2.empty-node:only-child::before,
            .ProseMirror h3.empty-node:only-child::before,
            .ProseMirror h4.empty-node:only-child::before {
                content: 'Heading';
            }
            .ProseMirror p.empty-node:only-child::before, .ProseMirror:empty::before {
                content: 'Start typing...';
            }
            a .ProseMirror p.empty-node::before, a .ProseMirror:empty::before {
                content: '';
            }
            .mceText, .ProseMirror {
                white-space: pre-wrap;
            }
body, #bodyTable { background-color: rgb(244, 244, 239); }.mceText, .mceLabel { font-family: Roboto, "Helvetica Neue", Helvetica, Arial, sans-serif; }.mceText, .mceLabel { color: rgb(30, 27, 21); }.mceText h1 { margin-bottom: 0px; }.mceText p { margin-bottom: 0px; }.mceText label { margin-bottom: 0px; }.mceText input { margin-bottom: 0px; }.mceSpacing-24 .mceInput + .mceErrorMessage { margin-top: -12px; }.mceText h1 { margin-bottom: 0px; }.mceText p { margin-bottom: 0px; }.mceText label { margin-bottom: 0px; }.mceText input { margin-bottom: 0px; }.mceSpacing-12 .mceInput + .mceErrorMessage { margin-top: -6px; }.mceText h1 { margin-bottom: 0px; }.mceText p { margin-bottom: 0px; }.mceText label { margin-bottom: 0px; }.mceText input { margin-bottom: 0px; }.mceSpacing-48 .mceInput + .mceErrorMessage { margin-top: -24px; }.mceInput { background-color: transparent; border: 2px solid rgb(208, 208, 208); width: 60%; color: rgb(77, 77, 77); display: block; }.mceInput[type="radio"], .mceInput[type="checkbox"] { float: left; margin-right: 12px; display: inline; width: auto !important; }.mceLabel > .mceInput { margin-bottom: 0px; margin-top: 2px; }.mceLabel { display: block; }.mceText p { color: rgb(30, 27, 21); font-family: Roboto, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 18px; font-weight: normal; line-height: 1.5; text-align: left; letter-spacing: 0px; direction: ltr; }.mceText h1 { color: rgb(30, 27, 21); font-family: "Helvetica Neue", Helvetica, Arial, Verdana, sans-serif; font-size: 31px; font-weight: bold; line-height: 1.5; text-align: center; letter-spacing: 0px; direction: ltr; }.mceText a { color: rgb(0, 0, 0); font-style: normal; font-weight: normal; text-decoration: underline; direction: ltr; }
@media only screen and (max-width: 480px) {
            .mceText p { font-size: 16px !important; line-height: 1.5 !important; }
          }
@media only screen and (max-width: 480px) {
            .mceText h1 { font-size: 31px !important; line-height: 1.5 !important; }
          }
@media only screen and (max-width: 480px) {
            .mceBlockContainer { padding-left: 16px !important; padding-right: 16px !important; }
          }
#dataBlockId-9 p, #dataBlockId-9 h1, #dataBlockId-9 h2, #dataBlockId-9 h3, #dataBlockId-9 h4, #dataBlockId-9 ul { text-align: center; }
@media only screen and (max-width: 480px) {
        .mobileClass-4 {padding-left: 12 !important;padding-top: 0 !important;padding-right: 12 !important;}
      }</style>                 <link rel="stylesheet" href="./wholething_files/archivebar-desktop.css" mc:nocompile="">  
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("True"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA",function(){function e(){if(!r){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,o.appendChild(e),r=!0}}function t(e){r=!0;var n,t,a,i,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(o,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",i=(a.frameElement||a).style,i.width=0,i.height=0,i.border=0,i.display="none",o.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void 0;",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=14,window.BOOMR.url=n+"QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA";var i=document.currentScript||document.getElementsByTagName("script")[0],o=i.parentNode,r=!1,d=document.createElement("link");if(d.relList&&"function"==typeof d.relList.supports&&d.relList.supports("preload")&&"as"in d)window.BOOMR.snippetMethod="p",d.href=window.BOOMR.url,d.rel="preload",d.as="script",d.addEventListener("load",e),d.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!r)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),o.appendChild(d);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="",a="jj6l2atinrupgziutn7a-f-3394b93a3-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"36","ak.cp":"641026","ak.ai":parseInt("761902",10),"ak.ol":"0","ak.cr":25,"ak.ipv":4,"ak.proto":"h2","ak.rid":"25aa8c0","ak.r":33370,"ak.a2":n,"ak.m":"x","ak.n":"essl","ak.bpcip":"74.124.189.0","ak.cport":58277,"ak.gh":"23.46.238.134","ak.quicv":"","ak.tlsv":"tls1.3","ak.0rtt":"","ak.csrc":"-","ak.acc":"","ak.t":"1695849342","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==kLrz6sw+o4C0H0NkPi2+lc/vW5ydRZh+tIj2jfVoHpTSL0AE7aLCH34jYyS7/XX531isE0KKZlCnyck4B02I4RPaPNSerb+USn4ZI34n9NmUAfpR0DirrBtrHimqyrMHMHqo997j1o5XUCxbkEq0UsNOKkmIqdHBBj+ggfOAEgIOQGcvEB3KK1NdOivO8kJqU3sgpkppsgaiLoq2X0fbSe40pMlnLNCDl/3Lo7Xhbc0PE1E+qN8R/WavRZ8pFE+oisU2uzrgFgVHUB3I+HBLl0/m0vC2OT3I6WGYhoOrZhNg2Vu2VrohWFc5ZDqKdvVk9L5fyPLC7pyS30wOEPbuoPPMjACQelx0rQRTYQjlt90OoKatLzZFWj67oRmIrJ1S6QxJC99Plf+EMYO7leaPBQkf3GSIMOMFzNjpNrRqlpY=","ak.pv":"84","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="./wholething_files/QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA" rel="preload" as="script"><script id="boomr-scr-as" src="./wholething_files/QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA" async=""></script></head> <body id="archivebody"> <div id="awesomewrap"> <div id="awesomeshare"> <div id="zclipwrap"> <div class="copy-container"> <label for="clipboardSource">Campaign URL</label> <span id="copyURL"> <input id="clipboardSource" name="shorturl" style="margin-top:6px;" type="text" value="https://us21.campaign-archive.com/?u=506ac9dc6e88b1ae3fedcece9&amp;id=6357ab3f35" class="av-text"> <a id="copyToClipboard" href="javascript:;">Copy</a> </span> </div>  </div> <ul id="awesomesocial"> <li class="twt"> <div> <a title="Share on Twitter" target="_blank" href="https://twitter.com/share?url=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35" rel="noopener noreferrer">Twitter <b>0 <i>tweets</i></b></a> </div>  </li> </ul> </div> <ul id="awesomebar"> <li> <a href="http://eepurl.com/isHCgI" title="Subscribe to List" target="_blank" rel="noopener noreferrer">Subscribe</a> </li> <li class="float-r more"><a href="javascript:;" data-to-toggle="#translate">Translate</a> <ul id="translate"> <li> <a rel="nofollow" title="English" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|en&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">English</a> </li><li> <a rel="nofollow" title="العربية" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ar&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">العربية</a> </li><li> <a rel="nofollow" title="Afrikaans" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|af&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Afrikaans</a> </li><li> <a rel="nofollow" title="беларуская мова" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|be&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">беларуская мова</a> </li><li> <a rel="nofollow" title="български" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|bg&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">български</a> </li><li> <a rel="nofollow" title="català" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ca&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">català</a> </li><li> <a rel="nofollow" title="中文（简体）" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|zh-CN&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">中文（简体）</a> </li><li> <a rel="nofollow" title="中文（繁體）" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|zh-TW&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">中文（繁體）</a> </li><li> <a rel="nofollow" title="Hrvatski" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|hr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Hrvatski</a> </li><li> <a rel="nofollow" title="Česky" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|cs&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Česky</a> </li><li> <a rel="nofollow" title="Dansk" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|da&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Dansk</a> </li><li> <a rel="nofollow" title="eesti&amp;nbsp;keel" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|et&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">eesti&nbsp;keel</a> </li><li> <a rel="nofollow" title="Nederlands" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|nl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Nederlands</a> </li><li> <a rel="nofollow" title="Suomi" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|fi&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Suomi</a> </li><li> <a rel="nofollow" title="Fran&amp;ccedil;ais" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|fr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Français</a> </li><li> <a rel="nofollow" title="Deutsch" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|de&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Deutsch</a> </li><li> <a rel="nofollow" title="&amp;Epsilon;&amp;lambda;&amp;lambda;&amp;eta;&amp;nu;&amp;iota;&amp;kappa;ή" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|el&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Ελληνική</a> </li><li> <a rel="nofollow" title="हिन्दी" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|hi&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">हिन्दी</a> </li><li> <a rel="nofollow" title="Magyar" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|hu&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Magyar</a> </li><li> <a rel="nofollow" title="Gaeilge" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ga&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Gaeilge</a> </li><li> <a rel="nofollow" title="Indonesia" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|id&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Indonesia</a> </li><li> <a rel="nofollow" title="íslenska" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|is&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">íslenska</a> </li><li> <a rel="nofollow" title="Italiano" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|it&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Italiano</a> </li><li> <a rel="nofollow" title="日本語" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ja&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">日本語</a> </li><li> <a rel="nofollow" title="ភាសាខ្មែរ" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|km&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">ភាសាខ្មែរ</a> </li><li> <a rel="nofollow" title="한국어" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ko&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">한국어</a> </li><li> <a rel="nofollow" title="македонски&amp;nbsp;јазик" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|mk&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">македонски&nbsp;јазик</a> </li><li> <a rel="nofollow" title="بهاس ملايو" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ms&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">بهاس ملايو</a> </li><li> <a rel="nofollow" title="Malti" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|mt&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Malti</a> </li><li> <a rel="nofollow" title="Norsk" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|no&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Norsk</a> </li><li> <a rel="nofollow" title="Polski" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|pl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Polski</a> </li><li> <a rel="nofollow" title="Portugu&amp;ecirc;s" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|pt&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Português</a> </li><li> <a rel="nofollow" title="Portugu&amp;ecirc;s&amp;nbsp;-&amp;nbsp;Portugal" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|pt-PT&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Português&nbsp;-&nbsp;Portugal</a> </li><li> <a rel="nofollow" title="Rom&amp;acirc;nă" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ro&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Română</a> </li><li> <a rel="nofollow" title="Русский" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ru&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Русский</a> </li><li> <a rel="nofollow" title="Espa&amp;ntilde;ol" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|es&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Español</a> </li><li> <a rel="nofollow" title="Kiswahili" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sw&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Kiswahili</a> </li><li> <a rel="nofollow" title="Svenska" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sv&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Svenska</a> </li><li> <a rel="nofollow" title="עברית" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|iw&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">עברית</a> </li><li> <a rel="nofollow" title="Lietuvių" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|lt&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Lietuvių</a> </li><li> <a rel="nofollow" title="latviešu" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|lv&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">latviešu</a> </li><li> <a rel="nofollow" title="slovenčina" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sk&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">slovenčina</a> </li><li> <a rel="nofollow" title="slovenščina" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">slovenščina</a> </li><li> <a rel="nofollow" title="српски" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">српски</a> </li><li> <a rel="nofollow" title="தமிழ்" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ta&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">தமிழ்</a> </li><li> <a rel="nofollow" title="ภาษาไทย" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|th&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">ภาษาไทย</a> </li><li> <a rel="nofollow" title="Türkçe" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|tr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Türkçe</a> </li><li> <a rel="nofollow" title="Filipino" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|tl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Filipino</a> </li><li> <a rel="nofollow" title="украї́нська" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|uk&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">украї́нська</a> </li><li> <a rel="nofollow" title="Tiếng&amp;nbsp;Việt" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|vi&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Tiếng&nbsp;Việt</a> </li> </ul> </li> </ul> </div>
        
<!---->
<!--[if !gte mso 9]><!----><span class="mcnPreviewText" style="display:none; font-size:0px; line-height:0px; max-height:0px; max-width:0px; opacity:0; overflow:hidden; visibility:hidden; mso-hide:all;">Gracell doses first patient in Phase 1/2 ... Ionis has entered an agreement with Roche for two novel RNA-targeted programs ...</span><!--<![endif]-->
<!---->
<center>
<table border="0" cellpadding="0" cellspacing="0" height="100%" width="100%" id="bodyTable" style="background-color: rgb(244, 244, 239);">
<tbody><tr>
<td class="bodyCell" align="center" valign="top">
<table id="root" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody data-block-id="13" class="mceWrapper"><tr><td align="center" valign="top" class="mceWrapperOuter"><!--[if (gte mso 9)|(IE)]><table align="center" border="0" cellspacing="0" cellpadding="0" width="660" style="width:660px;"><tr><td><![endif]--><table border="0" cellpadding="0" cellspacing="0" width="100%" style="max-width:660px" role="presentation"><tbody><tr><td style="background-color:#f4f4ef;background-position:center;background-repeat:no-repeat;background-size:cover" class="mceWrapperInner" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="12"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td style="padding-top:0;padding-bottom:0" class="mceColumn" data-block-id="-8" valign="top" colspan="12" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td style="padding-top:48px;padding-bottom:12px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="1" class="mceText" id="dataBlockId-1" style="width:100%"><p class="last-child"> </p></div></td></tr><tr><td style="padding-top:12px;padding-bottom:5px;padding-right:48px;padding-left:48px" class="mceBlockContainer" align="center" valign="top"><img data-block-id="2" width="369" height="auto" style="width:369px;height:auto;max-width:100%;display:block" alt="" src="./wholething_files/45e2461b-dab9-a382-7d85-fbc2f179c6a4.png" role="presentation" class="imageDropZone"></td></tr><tr><td style="padding-top:0;padding-bottom:12px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="16" class="mceText" id="dataBlockId-16" style="width:100%"><h1 style="text-align: center;" class="last-child"><span style="color:#80807f;"><span style="font-size: 20px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"><span style="font-weight:normal;">Pharma Intelligence for Industry Leaders</span></span></span></span></h1></div></td></tr><tr><td style="background-color:transparent;padding-top:20px;padding-bottom:20px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color:transparent" role="presentation" data-block-id="15"><tbody><tr><td style="min-width:100%;border-top:2px solid #7c7e73" valign="top"></td></tr></tbody></table></td></tr><tr><td style="background-color:transparent;padding-top:20px;padding-bottom:20px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="18" class="mceText" id="dataBlockId-18" style="width:100%"><h1 style="line-height: 1.25;" class="last-child">Gracell's Clinical Trial, Ionis-Roche Partnership, VBI's Vaccine Progress</h1></div></td></tr><tr><td style="background-color:transparent;padding-top:20px;padding-bottom:20px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color:transparent" role="presentation" data-block-id="19"><tbody><tr><td style="min-width:100%;border-top:2px solid #7c7e73" valign="top"></td></tr></tbody></table></td></tr><tr><td style="background-color:transparent;padding-top:12px;padding-bottom:5px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="3" class="mceText" id="dataBlockId-3" style="width:100%"><p style="line-height: 2; text-align: left;"><span style="text-decoration:underline;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Post-market Yesterday</span></span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Gracell Biotechnologies</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has dosed its first patient in a Phase 1b/2 clinical trial evaluating GC012F for treating relapsed/refractory multiple myeloma. This marks a significant milestone in their clinical development pipeline.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Galecto</span></span></span></strong><span style="color:#1319fb;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">has announced plans to explore strategic alternatives. This could potentially result in significant changes to the company's future operations and strategic direction.</span></span></p><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> <br></span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Rocket Pharmaceuticals</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> will participate in the Chardan 7th Annual Genetic Medicines Conference. This participation demonstrates the company's ongoing commitment to engaging in industry dialogues.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">MEI Pharma</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has reported its fiscal year 2023 results and operational highlights. The report details the company's performance and gives insight into its future plans.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Adverum Biotechnologies</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has announced positive Aflibercept protein level data from the LUNA Phase 2 trial. This positive data suggests progress in the company's clinical development.</span></span></p><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> <br></span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Cardiff Oncology</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has announced positive clinical data in pancreatic cancer and small cell lung cancer. The data showcases the potential of Onvansertib monotherapy as an effective treatment option.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 2; text-align: left;"><span style="color:#1e1b15;"><span style="text-decoration:underline;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Pre-market Today</span></span></span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">IDEAYA Biosciences</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has received fast track designation for IDE161. This designation could significantly expedite the development and review process for the drug.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Ionis</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has entered an agreement with </span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Roche</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease. This collaboration could potentially lead to breakthroughs in these two neurological diseases.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Precision BioSciences</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has received a U.S. patent allowance covering PBGENE-PMM for m.3243-associated mitochondrial diseases. This patent reinforces the company's intellectual property portfolio.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">VBI Vaccines</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">' pan-coronavirus vaccine candidate, VBI-2901, has induced broad and durable protective titers against variants of concern. This marks a significant step forward in the fight against COVID-19.</span></span></p><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> <br></span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Viatris</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">and </span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Ocuphire Pharma</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> have announced FDA approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)&nbsp;0.75%&nbsp;Eye Drops for the treatment of pharmacologically-induced Mydriasis. This approval expands the treatment options available to patients.</span></span></p><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> &nbsp;</span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Nektar Therapeutics</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> has announced a new clinical study collaboration with </span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Cellular Biomedicine Group</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> Inc. to evaluate NKTR-255 in combination with C-TIL051 in advanced non-small cell lung cancer. This collaboration could potentially lead to new treatment options for patients with this type of cancer.</span></span></p><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> &nbsp;</span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Ligand</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">has acquired assets of </span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Novan</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">, Inc. for&nbsp;$12.2 Million. This acquisition expands Ligand's portfolio and capabilities.</span></span></p><p><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Evofem</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">has announced that </span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Padagis</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">will not seek FDA approval to market a generic version of Phexxi® until Evofem's Phexxi patents expire. This announcement safeguards Evofem's market position in the interim.</span></span></p>
    <tr><td style="background-color:transparent;padding-top:0px;padding-bottom:20px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color:transparent" role="presentation" data-block-id="19"><tbody><tr><td style="min-width:100%;border-top:2px solid #7c7e73" valign="top"></td></tr></tbody></table></td></tr>
    
    
    <p class="last-child"><br></p></div></td></tr><tr><td style="padding-top:12px;padding-bottom:12px;padding-right:24px;padding-left:24px" class="mceBlockContainer" align="center" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" role="presentation" data-block-id="20"><tbody><tr class="mceStandardButton"><td style="background-color:#000000;border-radius:0;text-align:center" class="mceButton" valign="top"><a href="https://bancroft.ai/" target="_blank" style="background-color:#000000;border-radius:0;border:2px solid #000000;color:#ffffff;display:block;font-family:&#39;Helvetica Neue&#39;, Helvetica, Arial, Verdana, sans-serif;font-size:16px;font-weight:normal;font-style:normal;padding:16px 28px;text-decoration:none;min-width:30px;text-align:center;direction:ltr;letter-spacing:0px">subscribe at bancroft.ai</a></td></tr><tr>
<!--[if mso]>
<td align="center">
<v:roundrect xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:w="urn:schemas-microsoft-com:office:word"
href="https://bancroft.ai/"
style="v-text-anchor:middle; width:224.99px; height:54.22px;"
arcsize="0%"
strokecolor="#000000"
strokeweight="2px"
fillcolor="#000000">
<v:stroke dashstyle="solid"/>
<w:anchorlock />
<center style="
color: #ffffff;
display: block;
font-family: 'Helvetica Neue', Helvetica, Arial, Verdana, sans-serif;
font-size: 16;
font-style: normal;
font-weight: normal;
letter-spacing: 0px;
text-decoration: none;
text-align: center;
direction: ltr;"
>
subscribe at bancroft.ai
</center>
</v:roundrect>
</td>
<![endif]-->
</tr></tbody></table></td></tr><tr><td style="padding-top:12px;padding-bottom:12px;padding-right:0;padding-left:0" class="mceLayoutContainer" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="7"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="24" width="100%" role="presentation"><tbody><tr><td style="margin-bottom:24px" class="mceColumn" data-block-id="-7" valign="top" colspan="12" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td align="center" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="" role="presentation" class="mceClusterLayout" data-block-id="-6"><tbody><tr><td style="padding-left:24px;padding-top:10px;padding-right:24px" data-breakpoint="4" valign="top" class="mobileClass-4"><a href="https://linkedin.com/company/bancroft-ai/" style="display:block" target="_blank" data-block-id="-5"><img width="40" height="auto" style="border:0;width:40px;height:auto;max-width:100%;display:block" alt="LinkedIn icon" src="./wholething_files/linkedin-filled-dark-40.png" class=""></a></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr><tr><td style="padding-top:8px;padding-bottom:8px;padding-right:8px;padding-left:8px" class="mceLayoutContainer" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="11" id="section_7ab9ee1066b227d4bccb43d31ba3bcf5" class="mceFooterSection"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="12" width="100%" role="presentation"><tbody><tr><td style="padding-top:0;padding-bottom:0;margin-bottom:12px" class="mceColumn" data-block-id="-3" valign="top" colspan="12" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td style="padding-top:12px;padding-bottom:12px;padding-right:16px;padding-left:16px" class="mceBlockContainer" align="center" valign="top"><div data-block-id="9" class="mceText" id="dataBlockId-9" style="display:inline-block;width:100%"><p class="last-child"><em><span style="font-size: 12px">Copyright (C) 2023 bancroft ai. All rights reserved.</span></em><br><span style="font-size: 12px"></span><span style="font-size: 12px">Want to change how you receive these emails?</span><br><span style="font-size: 12px">You can </span><a href="https://bancroft.us21.list-manage.com/profile?u=506ac9dc6e88b1ae3fedcece9&amp;id=1d1c22cbd2&amp;e=[UNIQID]&amp;c=6357ab3f35"><span style="font-size: 12px">update your preferences</span></a><span style="font-size: 12px"> or </span><a href="https://bancroft.us21.list-manage.com/unsubscribe?u=506ac9dc6e88b1ae3fedcece9&amp;id=1d1c22cbd2&amp;e=[UNIQID]&amp;c=6357ab3f35"><span style="font-size: 12px">unsubscribe</span></a></p></div></td></tr><tr><td class="mceLayoutContainer" align="center" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="-2"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td class="mceColumn" data-block-id="-9" valign="top" colspan="12" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td align="center" valign="top"><div><div data-block-id="10"></div></div></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><!--[if (gte mso 9)|(IE)]></td></tr></table><![endif]--></td></tr></tbody></table>
</td>
</tr>
</tbody></table>
</center>
    <script src="./wholething_files/jquery.min.js.download"></script><script type="text/javascript">
            $(document).ready(function() {
                document.getElementById("copyToClipboard").addEventListener("click", function () {
                    var input = document.getElementById("clipboardSource");
                    input.select();
                    var successful = document.execCommand("copy");
                    if (successful) {
                        alert('Copied "' + input.value + '" to your clipboard.');
                    } else {
                        throw new Error("Failed to copy text (verify caller was in the context of an event handler)");
                    }
                });

                $('li.more > a').click(function(){
                    var toToggle = $($(this).attr('data-to-toggle'));
                    if(toToggle.is(':visible')){
                        toToggle.slideUp('fast');
                        $(this).removeClass('is-active');
                        if ($('#awesomebar').find('.is-active').length < 1){
                            $('#awesomebar').removeClass('sub-active');
                        }
                    } else {
                        toToggle.slideDown('fast');
                        $(this).addClass('is-active');
                        $('#awesomebar').addClass('sub-active');
                    }
                    return false;
                });

            });
        </script> 
</body></html>